Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing...